Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Schiff

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Taxol: a novel radiation sensitizerR B Tishler, P B Schiff, C R Geard, et al.
Cancer Research|March 15, 1993
Characterization of polyclonal and monoclonal anti-taxol antibodies and measurement of taxol in serumJ G Leu, B X Chen, P B Schiff, et al.
Cancer Research|June 15, 1992
Taxol sensitizes human astrocytoma cells to radiationR B Tishler, C R Geard, E J Hall, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2000
Dosimetric and volumetric criteria for selecting a source activity and a source type ((125)I or (103)Pd) in the presence of irregular seed placement in permanent prostate implantsC S Wuu, R D Ennis, P B Schiff, et al.
Radiation Protection Dosimetry|August 27, 2002
3D dosimetry study of 188Re liquid balloon for intravascular brachytherapy using bang polymer gel dosemetersC S Wuu, P B Schiff, M Maryanski, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 1996
Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteriesH I Amols, M Zaider, J Weinberger, et al.
International Journal of Radiation Oncology, Biology, Physics|September 1, 1993
Prostate-specific antigen density: a new prognostic indicator for prostate cancerP G Zentner, L K Pao, M C Benson, et al.
Anticancer Research|August 15, 1998
Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivityM Begemann, S A Kashimawo, D F Heitjan, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 1998
Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapyR D Ennis, B K Malyszko, D F Heitjan, et al.
Urology|July 1, 1997
Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancerA C Ingenito, R D Ennis, I C Hsu, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Taxol: a novel radiation sensitizerR B Tishler, P B Schiff, C R Geard, et al.
Cancer Research|March 15, 1993
Characterization of polyclonal and monoclonal anti-taxol antibodies and measurement of taxol in serumJ G Leu, B X Chen, P B Schiff, et al.
Cancer Research|June 15, 1992
Taxol sensitizes human astrocytoma cells to radiationR B Tishler, C R Geard, E J Hall, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2000
Dosimetric and volumetric criteria for selecting a source activity and a source type ((125)I or (103)Pd) in the presence of irregular seed placement in permanent prostate implantsC S Wuu, R D Ennis, P B Schiff, et al.
Radiation Protection Dosimetry|August 27, 2002
3D dosimetry study of 188Re liquid balloon for intravascular brachytherapy using bang polymer gel dosemetersC S Wuu, P B Schiff, M Maryanski, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 1996
Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteriesH I Amols, M Zaider, J Weinberger, et al.
International Journal of Radiation Oncology, Biology, Physics|September 1, 1993
Prostate-specific antigen density: a new prognostic indicator for prostate cancerP G Zentner, L K Pao, M C Benson, et al.
Anticancer Research|August 15, 1998
Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivityM Begemann, S A Kashimawo, D F Heitjan, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 1998
Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapyR D Ennis, B K Malyszko, D F Heitjan, et al.
Urology|July 1, 1997
Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancerA C Ingenito, R D Ennis, I C Hsu, et al.
Pageof 4